I agree that this site is using cookies. You can find further informations here.
X
Zarcos Pedrinaci, Irene
32  results:
Search for persons X
?
1

Trabectedin as second-line treatment in metastatic myxoid l..:

Pedrinaci, Irene Zarcos ; Jurado, José Miguel ; Carrillo, Josefa.
Journal of Medical Case Reports.  6 (2012)  1 - p. , 2012
Link: https://doi.org/10.1186/..
 
?
2

Influence of Diagnostic Delay on Survival Rates for Patient..:

Padilla-Ruiz, María ; Morales-Suárez-Varela, María ; Rivas-Ruiz, Francisco...
International Journal of Environmental Research and Public Health.  19 (2022)  6 - p. 3626 , 2022
Link: https://doi.org/10.3390/..
 
?
3

Factors that Influence Treatment Delay for Patients with Br..:

REDISSEC-CaMISS Group ; Padilla-Ruiz, María ; Zarcos-Pedrinaci, Irene...
Annals of Surgical Oncology.  , 2020
Link: https://doi.org/10.1245/..
 
?
4

Triple negative breast cancer subtypes and pathologic compl..:

Santonja, Angela ; Sánchez-Muñoz, Alfonso ; Lluch, Ana...
Oncotarget.  9 (2018)  41 - p. 26406-26416 , 2018
Link: https://doi.org/10.18632..
 
?
5

Factors Associated with Prolonged Patient-Attributable Dela..:

Zarcos-Pedrinaci, Irene ; Téllez, Teresa ; Rivas-Ruiz, Francisco...
Cancer Research and Treatment.  50 (2018)  4 - p. 1270-1280 , 2018
Link: https://doi.org/10.4143/..
 
?
6

Factors that influence treatment delay in patients with col..:

Zarcos-Pedrinaci, Irene ; Fernández-López, Alberto ; Téllez, Teresa...
Oncotarget.  8 (2016)  22 - p. 36728-36742 , 2016
Link: https://doi.org/10.18632..
 
?
7

Valor predictivo de respuesta a la quimioterapia neoadyuvan..:

Zarcos Pedrinaci, Irene
Zarcos Pedrinaci, I. Valor predictivo de respuesta a la quimioterapia neoadyuvante en densidad de dosis, de los criterios de respuestas citológicos (CYCAR), en pacientes con cáncer de mama localizado. Granada: Universidad de Granada, 2016. [http://hdl.handle.net/10481/42053].  , 2016
Link: http://hdl.handle.net/10..
 
?
8

Trabectedin as second-line treatment in metastatic myxoid l..:

Pedrinaci, Irene Zarcos ; Jurado, José Miguel ; Carrillo, Josefa.
http://www.jmedicalcasereports.com/content/6/1/424.  , 2012
Link: http://www.jmedicalcaser..
 
?
9

Trabectedin as second-line treatment in metastatic myxoid l..:

Pedrinaci Irene Zarcos ; Jurado José Miguel ; Carrillo Josefa.
http://www.jmedicalcasereports.com/content/6/1/424.  , 2012
Link: https://doi.org/10.1186/..
 
?
10

Influence of depression on survival of colorectal cancer pa..:

Varela-Moreno, Esperanza ; Rivas-Ruiz, Francisco ; Padilla Ruiz, María del Carmen...
Varela‐MorenoE,Rivas‐RuizF,Padilla‐RuizM,etal.Influenceofdepressiononsurvivalofcolorectalcancerpatientsdrawnfromalargeprospectivecohort.Psychooncology.2022;31(10):1762‐1773.https://doi.org/10.1002/pon.6018.  , 2022
Link: https://hdl.handle.net/1..
 
?
11

Influence of Diagnostic Delay on Survival Rates for Patient..:

Padilla-Ruiz, María ; Morales-Suárez-Varela, María ; Rivas-Ruiz, Francisco...
https://doi.org/10.3390/ijerph19063626.  , 2022
Link: http://hdl.handle.net/10..
 
?
12

Influence of Diagnostic Delay on Survival Rates for Patient..:

Padilla-Ruiz, María ; Morales-Suárez-Varela, María ; Rivas-Ruiz, Francisco...
http://hdl.handle.net/10668/21047.  , 2022
Link: http://hdl.handle.net/10..
 
?
13

First hospital contact via the Emergency Department is an i..:

Téllez, Teresa ; García-Aranda, Marilina ; Zarcos-Pedrinaci, Irene...
1130-0108.  , 2019
Link: http://hdl.handle.net/10..
 
?
14

Impact of adjuvant chemotherapy on the survival of patients..:

Zarcos-Pedrinaci, Irene ; Redondo, Maximino ; Louro, Javier...
http://hdl.handle.net/10668/14539.  , 2019
Link: http://hdl.handle.net/10..
 
?
15

Triple negative breast cancer subtypes and pathologic compl..:

Santonja, Ángela ; Sánchez-Muñoz, Alfonso ; Lluch, Ana...
Santonja A, Sánchez-Muñoz A, Lluch A, Chica-Parrado MR, Albanell J, Chacón JI, Antolín S, Jerez JM, de la Haba J, de Luque V, Fernández-De Sousa CE, Vicioso L, Plata Y, Ramírez-Tortosa CL, Álvarez M, Llácer C, Zarcos-Pedrinaci I, Carrasco E, Caballero R, Martín M, Alba E. Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. Oncotarget. 2018 May 29;9(41):26406-26416. doi:10.18632/oncotarget.25413. PMID: 29899867; PMCID: PMC5995183..  , 2018
Link: https://hdl.handle.net/1..
 
1-15